Drug Discovery & Development
Pfizer to acquire Seagen for $43 billion
Pfizer will acquire Seagen, a firm specializing in the discovery and development of treatments for cancer, the firms announced on Monday. Read More
Nasal antibody modulates inflammatory response in COVID-19 patients in small clinical trial
A nasally administered monoclonal antibody modulated inflammatory responses in COVID-19 patients in a small clinical trial. Read More
Light-controlled drug delivery platform opens opportunities to treat pain, cancer
A self-powered, light-controlled drug delivery platform could enable the controlled release of medicines and eliminate the need to surgically extract the implant after use, according to research published in the Proceedings of the National Academy of Sciences (PNAS). Read More
Immune homing mechanism enables targeted drug delivery to pediatric brain tumors in mice
Piggybacking on the homing mechanism that the immune system uses to direct white blood cells could enable the targeted delivery of drugs in children with brain tumors, according to research published on Thursday in Nature Materials. Read More
COVID-19 vaccine development: Public funding yielded private profits
Decades before the COVID-19 pandemic, the U.S. government invested at least $337 million into critical research that led to mRNA COVID-19 vaccines. The government also paid $31.6 billion during the pandemic for vaccine research, production, and vaccines for all Americans. Read More
At SLAS 2023, companies showcase, launch advanced automation and screening technologies
At the Society for Laboratory Automation and Screening (SLAS) 2023 International Conference and Exhibition, being held in San Diego from February 25 to March 1, numerous firms have announced that they are showcasing emerging technologies for advanced life science applications. Read More
Agilent launches cell analysis workflow automation for immuno-oncology, virology, and vaccine development
Agilent Technologies on Friday announced that it has integrated its xCelligence RTCA HT (real-time cell analysis high-throughput) platform with the firm’s BioTek BioSpa 8 Automated Incubator, enabling a higher level of workflow automation. Read More
Survey finds physicians are comfortable prescribing Humira biosimilars if treatments are interchangeable
Most specialist physicians would be comfortable prescribing biosimilar versions of adalimumab (Humira), giving a boost to the companies seeking to capitalize on its loss of exclusivity. Read More
Meta-analysis reveals which antibody appears best at preventing RSV infection
A meta-analysis has found an investigational antibody is as effective at preventing respiratory syncytial virus (RSV) infection and associated negative health outcomes as the incumbent product. Read More
Multidrug-resistant bacteria cooperate to reduce the impact of antibiotics: study
Two of the most dangerous multidrug-resistant pathogens work together to nullify antibiotics, suggesting physicians need to determine if both bacteria are present before selecting a treatment regimen. Read More
Conferences
Science Briefs
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter